GF Fund Management CO. LTD. Makes New Investment in Exelixis, Inc. (NASDAQ:EXEL)

GF Fund Management CO. LTD. bought a new position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 5,996 shares of the biotechnology company's stock, valued at approximately $200,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in shares of Exelixis by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 29,429,252 shares of the biotechnology company's stock worth $979,994,000 after acquiring an additional 121,750 shares during the last quarter. LSV Asset Management raised its position in Exelixis by 0.8% during the fourth quarter. LSV Asset Management now owns 8,169,847 shares of the biotechnology company's stock valued at $272,056,000 after purchasing an additional 67,470 shares in the last quarter. Fuller & Thaler Asset Management Inc. lifted its stake in Exelixis by 10.2% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 7,630,940 shares of the biotechnology company's stock worth $254,110,000 after purchasing an additional 708,312 shares during the last quarter. Invesco Ltd. lifted its stake in Exelixis by 308.1% during the fourth quarter. Invesco Ltd. now owns 3,975,241 shares of the biotechnology company's stock worth $132,376,000 after purchasing an additional 3,001,204 shares during the last quarter. Finally, AQR Capital Management LLC boosted its holdings in shares of Exelixis by 25.7% in the 4th quarter. AQR Capital Management LLC now owns 3,967,005 shares of the biotechnology company's stock worth $132,101,000 after purchasing an additional 810,857 shares in the last quarter. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently weighed in on EXEL shares. Royal Bank of Canada reissued an "outperform" rating and set a $40.00 price objective on shares of Exelixis in a report on Wednesday, May 14th. HC Wainwright reissued a "buy" rating and set a $40.00 price target on shares of Exelixis in a research note on Thursday, March 27th. JMP Securities reaffirmed a "market outperform" rating and issued a $41.00 price objective on shares of Exelixis in a research note on Thursday, April 17th. Stifel Nicolaus upped their price objective on shares of Exelixis from $36.00 to $38.00 and gave the company a "hold" rating in a research note on Wednesday, May 14th. Finally, UBS Group reaffirmed an "underperform" rating on shares of Exelixis in a research note on Thursday, April 17th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $38.94.

Insiders Place Their Bets

In related news, EVP Patrick J. Haley sold 10,000 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $38.80, for a total value of $388,000.00. Following the completion of the transaction, the executive vice president now directly owns 341,028 shares in the company, valued at $13,231,886.40. This trade represents a 2.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Tomas J. Heyman sold 4,544 shares of Exelixis stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $44.29, for a total transaction of $201,253.76. Following the transaction, the director now directly owns 32,470 shares of the company's stock, valued at approximately $1,438,096.30. This trade represents a 12.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 459,276 shares of company stock worth $20,945,859. 2.82% of the stock is owned by corporate insiders.

Exelixis Price Performance

EXEL traded down $0.68 on Wednesday, hitting $42.41. The company had a trading volume of 2,891,889 shares, compared to its average volume of 2,311,846. The stock has a fifty day simple moving average of $38.14 and a 200-day simple moving average of $36.23. The firm has a market capitalization of $11.57 billion, a P/E ratio of 23.96, a P/E/G ratio of 1.13 and a beta of 0.25. Exelixis, Inc. has a 52-week low of $20.14 and a 52-week high of $48.85.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.